| Literature DB >> 29955172 |
Eliana Marisa Ramos1, Miryam Carecchio2,3,4, Roberta Lemos5, Joana Ferreira5, Andrea Legati1, Renee Louise Sears1, Sandy Chan Hsu1, Celeste Panteghini2, Luca Magistrelli6, Ettore Salsano7, Silvia Esposito3, Franco Taroni8, Anne-Claire Richard9, Christine Tranchant10,11, Mathieu Anheim10,11, Xavier Ayrignac12, Cyril Goizet13,14, Marie Vidailhet15, David Maltete16, David Wallon17, Thierry Frebourg9, Lylyan Pimentel5, Daniel H Geschwind1, Olivier Vanakker18, Douglas Galasko19, Brent L Fogel20, A Micheil Innes21, Alison Ross22, William B Dobyns23, Diana Alcantara24, Mark O'Driscoll24, Didier Hannequin25, Dominique Campion9,26, João R Oliveira5, Barbara Garavaglia2, Giovanni Coppola27, Gaël Nicolas28.
Abstract
Primary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying disorder with a wide spectrum of motor, cognitive, and neuropsychiatric symptoms. It is typically inherited as an autosomal-dominant trait with four causative genes identified so far: SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for primary brain calcification regardless of their family history. Sequence variants were classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either pathogenic or likely pathogenic variants (n = 34, 19.2%) or VUS (n = 11, 6.2%). SLC20A2 provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and PDGFRB (1.7%). A total of 81.5% of carriers were symptomatic and the most recurrent symptoms were parkinsonism, cognitive impairment, and psychiatric disturbances (52.3%, 40.9%, and 38.6% of symptomatic individuals, respectively), with a wide range of age at onset (from childhood to 81 years). While the pathogenic and likely pathogenic variants identified in this study can be used for genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated patients, in order to be classified as pathogenic.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29955172 PMCID: PMC6138755 DOI: 10.1038/s41431-018-0185-4
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246